Published

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Health policy (Amsterdam, Netherlands)
Date: 2025-11-01
Source: PubMed
DOI: 10.1016/j.healthpol.2025.105392
PubMed: 40694950

Authors

Joga R Yerram S Patnam JD Choudhary KK Varpe P Raghuvanshi RS Srivastava S

Watch author

Derived topics and classifications

psilocybin Depression PTSD Clinical Trial Review Article Treatment-Resistant Depression Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2The Journal of Clinical Psychiatry · 2021-02-23 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Psychedelics’ Use as Medicine Hits Significant RoadblockPsychiatric News · 2024-06-12 Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological DistressWestern CEDAR (Western Washington University) · 2018-01-01 Narrative therapy-assisted psilocybin use for treatment of depressionSeattle Pacific University Research Conference · 2017-01-01